Treatment of postmenopausal osteoporosis (Q74332861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

Treatment of postmenopausal osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

postmenopausal osteoporosis

10 November 2019

main subject

1 reference

Pierre D Delmas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

language of work or name

English

0 references

publication date

1 June 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

number of pages

9

1 reference

inferred from page(s)

published in

The Lancet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

9322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

2018-2026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Correcting calcium nutritional deficiency prevents spine fractures in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Annual injection of vitamin D and fractures of aged bones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Prevention of spinal osteoporosis in oophorectomised women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The effect of postmenopausal estrogen therapy on bone density in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Bone mass after withdrawal of oestrogen replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Fracture protection provided by long-term estrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Menopausal estrogen therapy and hip fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Hormone replacement therapy in the prevention and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Hormone replacement therapy and breast cancer. A review of current knowledge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Prospective study of exogenous hormones and risk of pulmonary embolism in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Cognitive function in postmenopausal women treated with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Pamidronate: An unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of salcatonin given intranasally on early postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Reconstructing the skeleton with intermittent parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Treatment of postmenopausal osteoporosis with calcitriol or calcium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Vitamin K intake and hip fractures in women: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Ipriflavone in the Treatment of Postmenopausal OsteoporosisA Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Stimulation of bone formation in vitro and in rodents by statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

High-intensity strength training in nonagenarians. Effects on skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

A multifactorial intervention to reduce the risk of falling among elderly people living in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of external hip protectors on hip fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Prevention of hip fracture in elderly people with use of a hip protector

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Risk of new vertebral fracture in the year following a fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Monitoring individual response to hormone replacement therapy with bone markers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908827-X

7 January 2021

10.1016/S0140-6736(02)08827-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12076571%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference